News & Media
Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration.
Many signaling pathways participate in both synaptic plasticity and neuronal degeneration. While calpains participate in these phenomena, very few studies have evaluated the respective roles of the two major calpain isoforms in the brain, calpain-1 and calpain-2. We review recent studies indicating that calpain-1 and calpain-2 exhibit opposite functions in both synaptic plasticity and neurodegeneration. Calpain-1 activation is required for the induction of long-term potentiation (LTP) and is generally neuroprotective, while calpain-2 activation limits the extent of potentiation and is neurodegenerative. This duality of functions is related to their associations with different PDZ-binding proteins, resulting in differential subcellular localization, and offers new therapeutic opportunities for a number of indications in which these proteases have previously been implicated.
NeurAegis Scientific Founder Michel Baudry Awarded $3.8M Grant from the Department of Defense to Advance Product Candidate for Treating Traumatic Brain Injury and Concussion
SOUTHBOROUGH, Mass., Sept. 5, 2019 /PRNewswire/ — NeurAegis, Inc., a privately held pharmaceutical company pioneering the development of breakthrough treatments for neurological disorders, announced today that its scientific founder, Dr. Michel Baudry, has been awarded a multi-year, $3.8 million grant from the Department of Defense’s Combat Casualty Care Research Program. This project is focused on optimizing a neuroprotective drug candidate for traumatic brain injury (TBI) and concussion and the DOD funds will support medicinal chemistry and preclinical studies in preparation for a first-in-human Phase I clinical trial.